Performance & GH axis
Andarine
S-4, GTx-007
Andarine is a selective androgen receptor modulator investigated for benign prostatic hyperplasia and muscle wasting. Development was discontinued and it is not approved anywhere.
Also known as: GTx-007
- Status
- Andarine is a research compound and not approved by the FDA for human use.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- Approximately 4 hours.
- How it's taken
- Oral, in non-clinical use
- Mechanism
- Anabolic (IGF-1 / myostatin)
- Pathways
- Androgen
How Andarine works
Andarine is a non-steroidal partial agonist at the androgen receptor with tissue selectivity for muscle and bone. As a partial agonist it can act as an antagonist in tissues with high androgen sensitivity, which was the basis for investigating it in prostatic hyperplasia. It does not aromatise or undergo 5-alpha-reduction.
What research has looked at
- Preclinical work showed increases in muscle and bone mass with reduced prostatic effect relative to testosterone.
- Its partial-agonist profile gave it a distinctive dual action, potentially reducing prostate volume while increasing lean mass.
- Orally active.
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- It causes a characteristic dose-dependent visual disturbance — a yellow tint to vision and impaired night vision — attributed to an interaction with retinal photoreceptors. This is well documented among users and is unusual among SARMs.
- Development was discontinued and no regulator has approved it. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- Suppression of endogenous testosterone and adverse changes in HDL cholesterol.
- The FDA has warned about SARMs as a class, citing liver injury and increased cardiovascular risk.
- Prohibited at all times under the WADA Prohibited List.
Sources
- PubMed research on andarine S-4 SARM visual disturbance · NIH · National Library of Medicine
- DrugBank record for andarine · DrugBank
- Active clinical trials for andarine · U.S. National Library of Medicine
Track Andarine in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Andarine FAQ
What is Andarine?
Andarine is a selective androgen receptor modulator investigated for benign prostatic hyperplasia and muscle wasting. Development was discontinued and it is not approved anywhere.
How does Andarine work?
Andarine is a non-steroidal partial agonist at the androgen receptor with tissue selectivity for muscle and bone. As a partial agonist it can act as an antagonist in tissues with high androgen sensitivity, which was the basis for investigating it in prostatic hyperplasia. It does not aromatise or undergo 5-alpha-reduction.
Is Andarine FDA approved?
No. Andarine is a research compound and not approved by the FDA for human use. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of Andarine?
Reported half-life: Approximately 4 hours.
How is Andarine taken?
Oral, in non-clinical use.
What side effects have been reported with Andarine?
Reported in the sources: It causes a characteristic dose-dependent visual disturbance — a yellow tint to vision and impaired night vision — attributed to an interaction with retinal photoreceptors. This is well documented among users and is unusual among SARMs; Development was discontinued and no regulator has approved it. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; Suppression of endogenous testosterone and adverse changes in HDL cholesterol; The FDA has warned about SARMs as a class, citing liver injury and increased cardiovascular risk; Prohibited at all times under the WADA Prohibited List.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.